Pharmaceutical industry
ALZA Corporation, a leading drug delivery systems company, and U.S. Bioscience Inc., a pharmaceutical company specializing in cancer and AIDS treatments, have signed a marketing and distribution agreement for Ethyol, a selective cytoprotective agent. The agreement grants ALZA exclusive rights to market Ethyol in the United States for five
Pharmaceutical industry
Seragen, Inc., a biotechnology company, has reported its third quarter financial results, showing a net loss of $5.6 million, or $0.34 per common share, compared to a net loss of $5.5 million in the same period last year. The company's total operating expenses for the
Pharmaceutical industry
ImmunoGen, a biopharmaceutical company, has engaged PaineWebber Inc. to help achieve its strategic partnering objectives. This partnership comes as a result of PaineWebber's prior experience as the lead underwriter in ImmunoGen's initial public offering and two subsequent offerings. ImmunoGen's Chairman and CEO, Mitchel Sayare,
Pharmaceutical industry
Rhone-Poulenc Rorer Inc. has received an approvable letter from the US Food and Drug Administration (FDA) for Taxotere, a new anticancer agent for the treatment of patients with locally advanced or metastatic breast cancer whose cancer has progressed during anthracycline-based therapy or has relapsed during adjuvant anthracycline-based therapy. This approval
Pharmaceutical industry
The Norwegian Medicines Control Authority has approved Taxotere, a new anticancer agent, for the treatment of metastatic breast cancer in patients who have received previous anthracycline-containing therapy or are not suitable for it. This approval makes Norway the first European country to approve Taxotere, providing a new treatment option for
Pharmaceutical industry
Guilford Pharmaceuticals, a biopharmaceutical company, has made significant progress in the development of GLIADEL, a revolutionary treatment for malignant brain cancer. The company has received clearance from the U.S. Food and Drug Administration (FDA) for its Treatment IND application for GLIADEL, a polymer implant that releases cancer chemotherapeutic drug
Pharmaceutical industry
The pharmaceutical company, U.S. Bioscience Inc., reported a significant loss of $5,887,500 for the third quarter ended September 30, 1995. The net loss per common share was 14 cents, a slight increase from the same period in the previous year. The loss includes an accrual of $2,
Pharmaceutical industry
CYTOGEN Corporation announced the successful acquisition of Cellcor Incorporated at a special meeting held on October 16, 1995, with over 95% of its stockholders voting in favor of the proposal. The approval marked a significant milestone in the biopharmaceutical company's strategy to add complementary products, technologies, and services
Pharmaceutical industry
Taxotere, a chemotherapy treatment developed by Rhone-Poulenc Rorer, has been recommended for approval in Australia for the treatment of advanced breast and non-small cell lung cancers that do not respond to initial therapy. This approval comes after Taxotere demonstrated significant response rates in clinical trials, with over half of patients
Pharmaceutical industry
France is the first country outside Japan to make Campto available to patients, marking a significant breakthrough in the treatment of colorectal cancer. Developed and brought to market by Rhone-Poulenc Rorer Inc. in near record time, Campto has demonstrated significant anti-tumor activity in patients with advanced colorectal cancer that has
Pharmaceutical industry
Isis Pharmaceuticals and Ciba-Geigy Limited have signed a letter of intent to broaden their collaboration in antisense research and development, with a focus on developing therapeutic compounds targeting isotypes of the protein kinase C (PKC) multi-gene family. This collaboration aims to discover additional therapeutic compounds and advance them through development,
Pharmaceutical industry
SUGEN, a biopharmaceutical company, has signed a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the clinical development of SU101, an anticancer compound. SU101 interacts with key cell signalling molecules, termed tyrosine kinases (TKs), and has been shown to selectively block signalling mediated by the
